XORTX Therapeutics (XRTX) Other Non-Current Liabilities (2020 - 2025)
XORTX Therapeutics (XRTX) posted Other Non-Current Liabilities of $24746.0 for Q3 2025, little changed on a QoQ basis from $24746.0 in Q2 2025, and little changed year-over-year from $24746.0 in Q3 2024.
XORTX Therapeutics (XRTX) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
XORTX Therapeutics' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $24746.0 for Q3 2025.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $24746.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $24746.0 (changed 0.0% YoY) and the FY2024 annual result came in at $24746.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities was $24746.0 for Q3 2025 at XORTX Therapeutics, roughly flat from $24746.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $25610.2 in Q3 2021 and bottomed at $23749.8 in Q4 2022.
- A 5-year average of $24858.6 and a median of $24746.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities declined 7.14% — and 2023, when it increased 4.19%.
- XORTX Therapeutics' Other Non-Current Liabilities stood at $25575.6 in 2021, then slipped by 7.14% to $23749.8 in 2022, then climbed by 4.19% to $24746.0 in 2023, then changed by 0.0% to $24746.0 in 2024, then changed by 0.0% to $24746.0 in 2025.
- Business Quant data shows XRTX's Other Non-Current Liabilities at $24746.0 in Q3 2025, $24746.0 in Q2 2025, and $24746.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 24,746.00 |
| Jun 30, 2025 | 24,746.00 |
| Mar 31, 2025 | 24,746.00 |
| Dec 31, 2024 | 24,746.00 |
| Sep 30, 2024 | 24,746.00 |
| Jun 30, 2024 | 24,746.00 |
| Mar 31, 2024 | 24,746.00 |
| Dec 31, 2023 | 24,746.00 |
| Sep 30, 2023 | 24,746.00 |
| Jun 30, 2023 | 24,746.00 |
| Mar 31, 2023 | 24,746.00 |
| Dec 31, 2022 | 23,749.83 |
| Sep 30, 2022 | 24,718.37 |
| Jun 30, 2022 | 25,285.57 |
| Mar 31, 2022 | 25,451.11 |
| Dec 31, 2021 | 25,575.57 |
| Sep 30, 2021 | 25,610.17 |
| Dec 31, 2020 | 24,728.31 |